Summary
Johnson & Johnson (J&J) engages in the research and development, manufacture and sale of a range of healthcare products. Its primary focus is on the development of products related to human health and well-being. The company provides pharmaceuticals in immunology, cancer, neuroscience, infectious, cardiovascular and metabolic diseases areas; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and consumer products through retail outlets and distributors. The company provides its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
Johnson & Johnson (JNJ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 13
List of Figures 20
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 24
Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 26
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28
Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details 61
Asset Purchase 61
Janssen Pharma Acquires CERC-501 from Cerecor 61
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 62
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 63
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 64
J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 65
Venture Financing 67
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 67
E-scape Bio Raises Additional USD8 Million in Series A Financing 69
DayTwo Secures USD12 Million in Series A Funding 70
DayTwo Raises USD12 Million in Series A Financing 71
Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 72
Biomx Raises USD24 Million in Series A Venture Financing 73
Pulmocide Raises USD30.4 Million in Series B Financing 74
Grail Raises USD914 Million in First Tranche of Series B Financing 76
Fusion Pharma Raises USD19 Million in Series A Financing 78
SuperX Raises USD11 Million in Series A Financing 79
Caelus Health Raises USD2.7 Million in Series A Financing 80
ApoGen Biotech Raises USD7 Million in Series A Financing 81
ReVision Optics Raises USD32 Million in Venture Financing 82
Blackthorn Therapeutics Raises USD40 Million in Series A Financing 84
V-Wave Raises USD28 Million in Venture Financing 85
Lodo Therapeutics Raises USD17 Million in Series A Financing 86
Aelix Therapeutics Raises USD12.7 Million in Series A Financing 88
Petra Pharma Raises USD48 Million in Series A Financing 89
Navitor Pharma Raises USD33 Million in Series B Financing 91
First Aid Shot Therapy Raises USD24 Million in Series C Financing 93
PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 94
Asceneuron Raises USD30.6 Million in Series A Financing 95
Merus Raises USD46.4 Million in First Tranche of Series C Financing 97
E-scape Bio Raises USD55 Million in Series A Financing 99
Alligator Bioscience to Raise Funds through Venture Financing 100
Protagonist Therapeutics Raises USD40 Million in Series C Financing 101
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 103
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 105
La Lumiere Raises USD20 Million in Series B Venture Financing 106
Tetra Discovery Raises Funds through Venture Financing 107
XW Labs Raises USD5.5 Million in Series A Financing 108
Inivata Raises USD6.5 Million in Venture Financing 109
Inviata Raises USD6.5 Million in Venture Financing 110
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 111
Ascelegen Therapeutics Raises Funds through Venture Financing 112
Padlock Therapeutics Raises Funds through Series A Financing 113
Navitor Pharma Raises USD24 Million in Series A Financing 114
Aduro BioTech Raises USD55 Million in Series C Financing 116
Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 117
Assembly Pharma Raises Funds Through Seed Financing 118
Alios BioPharma Raises US$41 Million In Series B Venture Financing 119
Covagen Raises US$50.3 Million In Series B Financing 120
Novira Therapeutics Raises US$28 Million In Series A Financing 122
SutroVax Raises Funds Through Initial Financing Round 124
TopiVert Raises USD28 Million in Venture Financing 125
TopiVert Raises US$7.4 Million In Venture Financing 126
Pulmocide Raises US$27.4 Million In Series A Financing 128
Biocartis Raises US$40.5 Million In Series E Financing 130
Merus Raises US$42 Million In Extended Series B Financing 132
Rodin Therapeutics Raises Funds Through Seed Financing 134
Vedanta Biosciences Raises Funds Through Venture Financing 135
XO1 Raises USD11 Million in Venture Financing 136
X01 Raises US$11 Million In Series A Financing 137
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 138
Novira Therapeutics Secures USD25 Million in Venture Funding 139
Aquinox Pharma Raises US$18 Million In Series C Financing 140
Biocartis Raises US$44.7 Million In Series D Financing 141
Genocea Biosciences Raises US$30 Million In Series C Financing 143
Aragon Pharma Raises US$50 Million In Series D Financing 145
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 146
Celladon Raises Additional US$10 Million In Series D Financing 148
Direct Flow Medical Secures USD0.28 Million in Venture Funding 150
Coherex Medical Secures USD16.5 Million in Venture Funding 151
Aragon Pharma Raises US$42 Million In Series C Financing 152
Biocartis Secures US$96 Million In Series C Financing Round 153
Novira Therapeutics Secures US$1 Million In Second Round Of Seed Financing 155
Spinal Modulation Secures US$30 Million In Series D Financing 156
23andMe Raises Additional USD9 Million in Series C Financing 158
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 159
Private Equity 161
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 161
Water Street Healthcare Partners Acquires OraPharma 162
Partnerships 163
Janssen Amends Licensing Agreement with Gilead for STR 163
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 164
Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 165
Proteros biostructures Enters into Research Agreement with Janssen Biotech 166
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 167
Idorsia and Janssen Biotech to Enter into option Agreement 168
Monash University Enters into Research Agreement with Janssen Biotech 169
Phagelux Enters into Agreement with Johnson & Johnson Consumer 170
Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 171
PeptiDream Enters into Agreement with Janssen Pharma 172
Janssen Pharma Enters into Partnership with Premier 173
Renova Therapeutics Enters into Agreement with Janssen Pharma 174
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 175
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 176
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 177
Janssen Research & Development Enters into Agreement with ChemDiv 178
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 179
Enamine Expands Agreement with Actelion 180
Karolinska Institutet Partners with Johnson & Johnson Companies 181
Janssen Biotech Enters into Partnership with Bristol-Myers 182
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 183
Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 184
Janssen Pharma Enters into Partnership with Bird Rock Bio 185
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 186
Janssen Pharma and Medicines for Malaria Venture to Develop Injectable Anti-Malarial Agents 187
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 188
HitGen Enters into Agreement with Janssen Biotech 189
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 190
Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 191
Philogen Enters into Co-Development Agreement with Janssen Biotech 192
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 193
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 194
Amyris Enters into Research Agreement with Janssen Biotech 195
Janssen Research & Development Enters into Agreement with Genentech 196
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 197
DiamiR Enters into Research Agreement with Janssen Pharma 198
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 199
Janssen Biotech Enters into Agreement with HUB foundation 200
Janssen Pharma Enters into Agreement with University of Pennsylvania 201
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 202
Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 203
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 204
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 205
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 206
Janssen Pharma Enters into Agreement with University of California, San Diego 207
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 208
Johnson & Johnson Consumer Enters into Agreement with BioMed X 209
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 210
Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 211
Janssen Biotech Enters into Agreement with Eureka Therapeutics 212
Intrexon Enters into Research Agreement with Janssen Pharma 213
Cypralis Enters into Research Agreement with Janssen Pharma 214
Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 215
Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 216
SynAging Extends Agreement with Actelion Pharma 217
ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 218
Nuevolution Enters into Discovery Agreement with Janssen Biotech 219
enGene Enters into Agreement with Janssen Biotech 220
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 221
BlinkBio Enters into Discovery Agreement with Janssen Pharma 222
UbiVac Enters into Agreement with Janssen Biotech 223
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 224
Nextera Enters into Research Agreement with Janssen Biotech 225
Handok Enters into Agreement with Actelion Pharmaceuticals 226
Actelion Forms Joint Venture with Max Planck Society 227
Johnson & Johnson Enters into Agreement with University of the Witwatersrand 228
Janssen Cilag Enters into Agreement with UniQuest 229
Johnson & Johnson Innovation Enters into Research Agreement with Washington University 230
Janssen Biotech Enters into Research Agreement with Emulate 231
Johnson & Johnson Innovation Partners with Lead Discovery Center 232
AC Immune Enters into Research Agreement with Janssen Pharma 233
X-Chem Expands Agreement with Janssen Biotech 234
Vectura Enters into Development and License Agreement with Janssen Biotech 235
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 236
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 237
Atreca Enters into Research Agreement with Janssen Biotech 238
Vaccinex Enters into Research Agreement with Janssen Research & Development 239
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 240
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 241
Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 242
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 243
Alector Enters Into Research Agreement With Janssen Pharma 244
Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 245
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 246
Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 247
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 248
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 249
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 250
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 251
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 252
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 253
Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 254
Open Monoclonal Expands Agreement with CNA Development 255
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 256
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 257
ex scientia Enters into Agreement with Janssen Research & Development 259
Mellitech Enters into Agreement with Janssen Pharma 260
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 261
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 262
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 263
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 264
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 265
Beactica Enters Into Research Agreement With Janssen Research & Development 266
Janssen-Cilag Enters Into Research Agreement With University of Melbourne 267
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 268
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 269
Selventa Enters Into Co-Development Agreement With Janssen Research & Development 270
Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 271
Dendright Enters Into Research Agreement With Janssen-Cilag 272
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 273
ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 274
Molecular Partners Enters Into Research Agreement With Janssen Biotech 275
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 276
Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharma 277
Jubilant Enters Into Drug Discovery Agreement With Janssen Pharmaceutica 278
ChemRar High Tech Center Enters Into Co-Development Agreement With Janssen Pharma 279
Synthes Enters Into Co-Development Agreement With Eli Lilly 280
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 281
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 282
Beactica Enters Into An Agreement With Janssen 283
Merck Amends Distribution Agreement With Johnson & Johnson 284
Medivir Enters Into Collaboration With Janssen Pharmaceutica 286
Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 287
Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 288
Veridex Enters Into Co-Development Agreement With Massachusetts General Hospital 289
Stereotaxis Amends Co-Development Agreement With Biosense Webster 290
Licensing Agreements 291
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 291
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 292
Pulmatrix Enters into Licensing Agreement with RespiVert 293
Janssen Biotech to Enter into Licensing Agreement with Protagonist Therapeutics 294
Janssen Pharma Enters into Licensing Agreement with Medivir 296
Janssen Biotech Enters into Licensing Agreement with Trianni 297
Janssen Biotech Enters into Licensing Agreement with Ablexis 298
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 299
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 301
CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 302
OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 303
BenevolentAI Enters into Licensing Agreement with Janssen Pharma 304
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 305
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 306
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 307
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 308
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 309
Janssen Biotec Enters into Licensing Agreement with MacroGenics 310
Janssen Biotech Enters into Licensing agreement with Tesaro 311
Janssen Pharma Enters into Licensing Agreement with Achillion Pharma 312
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 314
MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 315
Janssen Expands Licensing Agreement with Gilead 317
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 318
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 320
Minerva Amends licenses Agreement with Janssen Pharma for MIN-202 322
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 324
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 325
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 326
ViaCyte Enters into Licensing Agreement with Janssen Biotech 327
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 328
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 329
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 330
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 331
Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 332
Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 333
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 334
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 335
BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 336
Poseida Therapeutics Enters into Licensing Agreement with Janssen 337
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 338
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 339
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 340
Gour Medical Enters into Licensing Agreement with Actelion Pharma 341
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 342
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 343
AC Immune Enters into Licensing Agreement with Janssen Pharma 344
Kura Oncology Expands Licensing Agreement with Janssen Pharma 345
Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 347
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 348
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 349
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 350
AB-Biotics Enters into Licensing Agreement with Cilag 351
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 352
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 353
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 354
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 355
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 356
Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 357
Janssen Pharma Enters into Licensing Agreement with BiocerOX 359
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 360
Orion Enters Into Licensing Agreement With Janssen Pharma 361
CSL Enters Into Licensing Agreement With Janssen For CSL-362 362
Genmab Expands Licensing Agreement With Janssen Biotech 363
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 364
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 366
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 367
Intravacc Enters into Licensing Agreement with Crucell Holland 368
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 369
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 370
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 371
BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 372
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 373
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 374
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 375
Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 376
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 377
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 378
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 379
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 380
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 381
Shionogi Enters Into Licensing Agreement With Janssen Pharma 383
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 384
Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 386
Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 387
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 389
Depomed Enters Into Licensing Agreement With Janssen Pharma 390
Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 391
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 392
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 394
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 395
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 397
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 398
Biotoscana Extends Licensing Agreement With Actelion Pharma For Tracleer 399
GlaxoSmithKline Enters into Licensing Agreement with Janssen Biologics 400
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 401
Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 402
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 403
Topivert Enters into Licensing Agreement with RespiVert 405
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 406
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 407
Alios BioPharma Enters Into Licensing Agreement With Versitech 408
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For MTKi-327 409
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For Intetumumab 410
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 411
Vertex Pharma Enters Into Licensing Agreement With Alios BioPharma For ALS-2200 And ALS-2158 412
Isconova Expands Licensing Agreement With Crucell 414
AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 415
Cenix BioScience Enters Into Licensing Agreement With Janssen 416
Bioceros Expands Licensing Agreement With Crucell 417
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 418
Pepscan Therapeutics Enters Into Licensing Agreement With Crucell Holland 419
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 420
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 422
Tibotec Pharma Enters Into Licensing Agreement With Hetero Drugs For TMC278 423
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 424
Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharma 425
Equity Offering 426
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 426
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 428
Alligator Bioscience Raises USD252.8 Million in IPO 429
Tesaro Raises USD50 Million in Private Placement of Shares 431
Achillion Pharma Raises USD225 Million in Private Placement of Shares 432
Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 434
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 436
MacroGenics Raises USD75 Million in Private Placement of Common Stock 438
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 440
Debt Offering 441
Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 441
Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million 442
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million 444
Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million 446
Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million 448
Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million 450
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million 452
Actelion Pharma Completes Private Placement Of Convertible Bonds For US$254 Million 454
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$300 Million 455
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2013 For US$500 Million 457
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$900 Million 459
Johnson & Johnson Completes Public Offering Of 0.70% Senior Unsecured Notes Due 2013 For US$500 Million 461
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 463
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$450 Million 465
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 467
Asset Transactions 469
Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 469
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 470
Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 471
Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 472
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 473
Vivus Acquires Topiramate Related Patents from Janssen Pharma 475
Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 476
Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 477
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 478
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 480
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 481
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 482
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 483
Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million 484
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 485
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 486
Insight Pharma Acquires MONISTAT Business In North America From McNEIL-PPC 487
Ilex Consumer Products Acquires St. Joseph's Aspirin Brand From McNeil 488
Prestige Brands Completes Acquisition Of Dramamine Assets From McNeil-PPC 489
Acquisition 490
Johnson & Johnson Acquires Actelion for USD30 Billion 490
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 492
Ethicon Acquires Torax Medical 494
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 495
DePuy Orthopaedics Acquires BioMedical Enterprises 496
Johnson & Johnson Consumer to Acquire NeoStrata 497
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 498
Johnson and Johnson May Sell Noramco 499
Johnson & Johnson Acquires Novira Therapeutics 500
Biosense Webster Acquires Coherex Medical 501
Actelion Plans to Acquire ZS Pharma 502
Actelion Rejects Acquisition Offer from Shire 503
Janssen Pharma Acquires XO1 504
Valneva Acquires Crucell Sweden for USD54 Million 505
Tetraphase Pharma May Sell Itself 506
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 507
Cilag Acquires Covagen 509
Novartis Acquires CoStim Pharma 510
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 512
Johnson & Johnson Completes Acquisition Of Aragon Pharma For US$1 Billion 514
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 516
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 517
Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 519
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 520
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 522
Janssen-Cilag Acquires CorImmun 523
Valeant Pharma Completes Acquisition Of Ortho Dermatologics From Janssen For US$345 Million 525
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 526
SuperGen Completes Acquisition Of Astex Therapeutics 527
Johnson & Johnson Acquires Crucell 530
Johnson & Johnson - Key Competitors 532
Johnson & Johnson - Key Employees 533
Johnson & Johnson - Locations And Subsidiaries 534
Head Office 534
Other Locations & Subsidiaries 534
Recent Developments 552
Strategy And Business Planning 552
Apr 05, 2016: Johnson & Johnson Announces Launch of New Global Public Health Strategy at Opening of New Operations in Africa 552
Financial Announcements 554
Jul 18, 2017: Johnson & Johnson Reports 2017 Second-Quarter Results 554
Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 556
Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 558
Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 560
Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 562
Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results 564
Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results 566
Jan 26, 2016: Johnson & Johnson Reports 2015 Fourth-Quarter Results 568
Corporate Communications 570
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 570
Sep 13, 2016: J&J submits Ebola vaccine regimen to WHO for EUAL 571
Feb 17, 2016: Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa 572
Jan 19, 2016: Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace 573
Jan 06, 2016: Johnson & Johnson Health and Wellness Solutions Teams with Plug and Play to Launch Health and Wellness Technology Accelerator 574
Legal and Regulatory 575
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 575
Jan 05, 2017: Missouri Court Denies J&J Request to Delay Talc-Related Cancer Trials 576
Feb 29, 2016: Baron & Budd Investigating Potential Lawsuits Against Johnson & Johnson Regarding Link Between Talcum Powder and Ovarian Cancer 577
Government and Public Interest 578
Jun 06, 2016: GHIT Fund Welcomes Ten New Par
List of Tables
Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23
Johnson & Johnson, Deals By Therapy Area, 2011 to YTD 2017 24
Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 26
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28
Janssen Pharma Acquires CERC-501 from Cerecor 61
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 62
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 63
Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 64
J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 65
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 67
E-scape Bio Raises Additional USD8 Million in Series A Financing 69
DayTwo Secures USD12 Million in Series A Funding 70
DayTwo Raises USD12 Million in Series A Financing 71
Aragon Pharmaceuticals Raises USD22 Million in Series B Round of Financing 72
Biomx Raises USD24 Million in Series A Venture Financing 73
Pulmocide Raises USD30.4 Million in Series B Financing 74
Grail Raises USD914 Million in First Tranche of Series B Financing 76
Fusion Pharma Raises USD19 Million in Series A Financing 78
SuperX Raises USD11 Million in Series A Financing 79
Caelus Health Raises USD2.7 Million in Series A Financing 80
ApoGen Biotech Raises USD7 Million in Series A Financing 81
ReVision Optics Raises USD32 Million in Venture Financing 82
Blackthorn Therapeutics Raises USD40 Million in Series A Financing 84
V-Wave Raises USD28 Million in Venture Financing 85
Lodo Therapeutics Raises USD17 Million in Series A Financing 86
Aelix Therapeutics Raises USD12.7 Million in Series A Financing 88
Petra Pharma Raises USD48 Million in Series A Financing 89
Navitor Pharma Raises USD33 Million in Series B Financing 91
First Aid Shot Therapy Raises USD24 Million in Series C Financing 93
PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 94
Asceneuron Raises USD30.6 Million in Series A Financing 95
Merus Raises USD46.4 Million in First Tranche of Series C Financing 97
E-scape Bio Raises USD55 Million in Series A Financing 99
Alligator Bioscience to Raise Funds through Venture Financing 100
Protagonist Therapeutics Raises USD40 Million in Series C Financing 101
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 103
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 105
La Lumiere Raises USD20 Million in Series B Venture Financing 106
Tetra Discovery Raises Funds through Venture Financing 107
XW Labs Raises USD5.5 Million in Series A Financing 108
Inivata Raises USD6.5 Million in Venture Financing 109
Inviata Raises USD6.5 Million in Venture Financing 110
ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 111
Ascelegen Therapeutics Raises Funds through Venture Financing 112
Padlock Therapeutics Raises Funds through Series A Financing 113
Navitor Pharma Raises USD24 Million in Series A Financing 114
Aduro BioTech Raises USD55 Million in Series C Financing 116
Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 117
Assembly Pharma Raises Funds Through Seed Financing 118
Alios BioPharma Raises US$41 Million In Series B Venture Financing 119
Covagen Raises US$50.3 Million In Series B Financing 120
Novira Therapeutics Raises US$28 Million In Series A Financing 122
SutroVax Raises Funds Through Initial Financing Round 124
TopiVert Raises USD28 Million in Venture Financing 125
TopiVert Raises US$7.4 Million In Venture Financing 126
Pulmocide Raises US$27.4 Million In Series A Financing 128
Biocartis Raises US$40.5 Million In Series E Financing 130
Merus Raises US$42 Million In Extended Series B Financing 132
Rodin Therapeutics Raises Funds Through Seed Financing 134
Vedanta Biosciences Raises Funds Through Venture Financing 135
XO1 Raises USD11 Million in Venture Financing 136
X01 Raises US$11 Million In Series A Financing 137
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 138
Novira Therapeutics Secures USD25 Million in Venture Funding 139
Aquinox Pharma Raises US$18 Million In Series C Financing 140
Biocartis Raises US$44.7 Million In Series D Financing 141
Genocea Biosciences Raises US$30 Million In Series C Financing 143
Aragon Pharma Raises US$50 Million In Series D Financing 145
PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 146
Celladon Raises Additional US$10 Million In Series D Financing 148
Direct Flow Medical Secures USD0.28 Million in Venture Funding 150
Coherex Medical Secures USD16.5 Million in Venture Funding 151
Aragon Pharma Raises US$42 Million In Series C Financing 152
Biocartis Secures US$96 Million In Series C Financing Round 153
Novira Therapeutics Secures US$1 Million In Second Round Of Seed Financing 155
Spinal Modulation Secures US$30 Million In Series D Financing 156
23andMe Raises Additional USD9 Million in Series C Financing 158
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 159
Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 161
Water Street Healthcare Partners Acquires OraPharma 162
Janssen Amends Licensing Agreement with Gilead for STR 163
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 164
Johnson & Johnson to Enter into Agreement with Institute of Microbial Technology 165
Proteros biostructures Enters into Research Agreement with Janssen Biotech 166
University of California San Diego School of Medicine Enters into Agreement with Janssen Pharma 167
Idorsia and Janssen Biotech to Enter into option Agreement 168
Monash University Enters into Research Agreement with Janssen Biotech 169
Phagelux Enters into Agreement with Johnson & Johnson Consumer 170
Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 171
PeptiDream Enters into Agreement with Janssen Pharma 172
Janssen Pharma Enters into Partnership with Premier 173
Renova Therapeutics Enters into Agreement with Janssen Pharma 174
Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 175
Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 176
Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 177
Janssen Research & Development Enters into Agreement with ChemDiv 178
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 179
Enamine Expands Agreement with Actelion 180
Karolinska Institutet Partners with Johnson & Johnson Companies 181
Janssen Biotech Enters into Partnership with Bristol-Myers 182
Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 183
Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 184
Janssen Pharma Enters into Partnership with Bird Rock Bio 185
Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 186
Janssen Pharma and Medicines for Malaria Venture to Develop Injectable Anti-Malarial Agents 187
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 188
HitGen Enters into Agreement with Janssen Biotech 189
Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 190
Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 191
Philogen Enters into Co-Development Agreement with Janssen Biotech 192
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 193
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 194
Amyris Enters into Research Agreement with Janssen Biotech 195
Janssen Research & Development Enters into Agreement with Genentech 196
Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 197
DiamiR Enters into Research Agreement with Janssen Pharma 198
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 199
Janssen Biotech Enters into Agreement with HUB foundation 200
Janssen Pharma Enters into Agreement with University of Pennsylvania 201
Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 202
Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 203
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 204
Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 205
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 206
Janssen Pharma Enters into Agreement with University of California, San Diego 207
Enterome Bioscience Enters into Research Agreement with Janssen Biotech 208
Johnson & Johnson Consumer Enters into Agreement with BioMed X 209
Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 210
Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 211
Janssen Biotech Enters into Agreement with Eureka Therapeutics 212
Intrexon Enters into Research Agreement with Janssen Pharma 213
Cypralis Enters into Research Agreement with Janssen Pharma 214
Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 215
Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 216
SynAging Extends Agreement with Actelion Pharma 217
ViroGin Biotech Enters into With Johnson & Johnson Innovation and Janssen Biotech 218
Nuevolution Enters into Discovery Agreement with Janssen Biotech 219
enGene Enters into Agreement with Janssen Biotech 220
OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 221
BlinkBio Enters into Discovery Agreement with Janssen Pharma 222
UbiVac Enters into Agreement with Janssen Biotech 223
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 224
Nextera Enters into Research Agreement with Janssen Biotech 225
Handok Enters into Agreement with Actelion Pharmaceuticals 226
Actelion Forms Joint Venture with Max Planck Society 227
Johnson & Johnson Enters into Agreement with University of the Witwatersrand 228
Janssen Cilag Enters into Agreement with UniQuest 229
Johnson & Johnson Innovation Enters into Research Agreement with Washington University 230
Janssen Biotech Enters into Research Agreement with Emulate 231
Johnson & Johnson Innovation Partners with Lead Discovery Center 232
AC Immune Enters into Research Agreement with Janssen Pharma 233
X-Chem Expands Agreement with Janssen Biotech 234
Vectura Enters into Development and License Agreement with Janssen Biotech 235
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 236
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 237
Atreca Enters into Research Agreement with Janssen Biotech 238
Vaccinex Enters into Research Agreement with Janssen Research & Development 239
Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 240
Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 241
Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 242
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 243
Alector Enters Into Research Agreement With Janssen Pharma 244
Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 245
University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 246
Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 247
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 248
Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 249
Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 250
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 251
ZoBio Enters Into Drug Discovery Agreement With Actelion Pharma For Fragment Ligands 252
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 253
Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 254
Open Monoclonal Expands Agreement with CNA Development 255
DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 256
Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 257
ex scientia Enters into Agreement with Janssen Research & Development 259
Mellitech Enters into Agreement with Janssen Pharma 260
Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 261
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 262
Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 263
Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 264
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 265
Beactica Enters Into Research Agreement With Janssen Research & Development 266
Janssen-Cilag Enters Into Research Agreement With University of Melbourne 267
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 268
Artes Biotechnology Enters Into Co-Development Agreement With Crucell 269
Selventa Enters Into Co-Development Agreement With Janssen Research & Development 270
Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 271
Dendright Enters Into Research Agreement With Janssen-Cilag 272
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 273
ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 274
Molecular Partners Enters Into Research Agreement With Janssen Biotech 275
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 276
Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharma 277
Jubilant Enters Into Drug Discovery Agreement With Janssen Pharmaceutica 278
ChemRar High Tech Center Enters Into Co-Development Agreement With Janssen Pharma 279
Synthes Enters Into Co-Development Agreement With Eli Lilly 280
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 281
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 282
Beactica Enters Into An Agreement With Janssen 283
Merck Amends Distribution Agreement With Johnson & Johnson 284
Medivir Enters Into Collaboration With Janssen Pharmaceutica 286
Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 287
Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 288
Veridex Enters Into Co-Development Agreement With Massachusetts General Hospital 289
Stereotaxis Amends Co-Development Agreement With Biosense Webster 290
Janssen Pharma Enters into Licensing Agreement with St Vincent’s Institute of Medical Research 291
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 292
Pulmatrix Enters into Licensing Agreement with RespiVert 293
Janssen Biotech to Enter into Licensing Agreement with Protagonist Therapeutics 294
Janssen Pharma Enters into Licensing Agreement with Medivir 296
Janssen Biotech Enters into Licensing Agreement with Trianni 297
Janssen Biotech Enters into Licensing Agreement with Ablexis 298
Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 299
Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 301
CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 302
OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 303
BenevolentAI Enters into Licensing Agreement with Janssen Pharma 304
Actelion Enters into Licensing Agreement with ReveraGen BioPharma 305
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 306
TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 307
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 308
Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 309
Janssen Biotec Enters into Licensing Agreement with MacroGenics 310
Janssen Biotech Enters into Licensing agreement with Tesaro 311
Janssen Pharma Enters into Licensing Agreement with Achillion Pharma 312
Kythera Biopharma Enters into Licensing Agreement with Actelion Pharma 314
MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 315
Janssen Expands Licensing Agreement with Gilead 317
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 318
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 320
Minerva Amends licenses Agreement with Janssen Pharma for MIN-202 322
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 324
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 325
Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 326
ViaCyte Enters into Licensing Agreement with Janssen Biotech 327
Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 328
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 329
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 330
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 331
Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 332
Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 333
Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 334
Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 335
BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 336
Poseida Therapeutics Enters into Licensing Agreement with Janssen 337
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 338
GBC-Atrial Enters into Licensing Agreement with Actelion Pharma 339
Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 340
Gour Medical Enters into Licensing Agreement with Actelion Pharma 341
Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 342
Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 343
AC Immune Enters into Licensing Agreement with Janssen Pharma 344
Kura Oncology Expands Licensing Agreement with Janssen Pharma 345
Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 347
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 348
Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 349
Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 350
AB-Biotics Enters into Licensing Agreement with Cilag 351
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 352
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 353
ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 354
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 355
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 356
Janssen R&D Ireland Extends Licensing Agreement With International Partnership For Microbicides 357
Janssen Pharma Enters into Licensing Agreement with BiocerOX 359
Amunix Expands Licensing Agreement With Janssen For XTEN Technology 360
Orion Enters Into Licensing Agreement With Janssen Pharma 361
CSL Enters Into Licensing Agreement With Janssen For CSL-362 362
Genmab Expands Licensing Agreement With Janssen Biotech 363
Covagen Expands Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 364
Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 366
Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 367
Intravacc Enters into Licensing Agreement with Crucell Holland 368
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 369
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 370
Janssen Pharma Enters Into Licensing Agreement With Scripps Research Institute For Infectious Diseases 371
BioLife Solutions Enters Into Licensing Agreement With Janssen Research & Development For CryoStor 372
Ascletis Enters Into Licensing Agreement With Janssen For TMC310911 373
Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 374
Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 375
Janssen Pharma Enters Into Licensing Agreement With Pharmstandard For Bedaquiline, Anti-Tuberculosis Drug 376
NewVac Enters Into Licensing Agreement With Janssen For Quisinostat 377
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 378
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 379
Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 380
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 381
Shionogi Enters Into Licensing Agreement With Janssen Pharma 383
Covagen Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma And Tanabe Research Labs 384
Mucosis To Enter Into Licensing Agreement With Crucell For Mimopath Technology 386
Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 387
ImmuNext Enters Into Licensing Agreement With Janssen Biotech 389
Depomed Enters Into Licensing Agreement With Janssen Pharma 390
Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 391
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 392
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 394
Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 395
Theratechnologies Enters Into Licensing Agreement With Actelion Pharma For Lipodystrophy Drug 397
Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 398
Biotoscana Extends Licensing Agreement With Actelion Pharma For Tracleer 399
GlaxoSmithKline Enters into Licensing Agreement with Janssen Biologics 400
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 401
Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 402
Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 403
Topivert Enters into Licensing Agreement with RespiVert 405
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 406
Furiex Enters Into Licensing Agreement With Janssen Pharmaceutica For MuDelta 407
Alios BioPharma Enters Into Licensing Agreement With Versitech 408
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For MTKi-327 409
BeiGene Enters Into Licensing Agreement With Janssen Pharmaceutica For Intetumumab 410
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 411
Vertex Pharma Enters Into Licensing Agreement With Alios BioPharma For ALS-2200 And ALS-2158 412
Isconova Expands Licensing Agreement With Crucell 414
AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 415
Cenix BioScience Enters Into Licensing Agreement With Janssen 416
Bioceros Expands Licensing Agreement With Crucell 417
Furiex Pharma Enters Into Licensing Agreement With Janssen Pharmaceutica For JNJ-Q2 418
Pepscan Therapeutics Enters Into Licensing Agreement With Crucell Holland 419
Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 420
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 422
Tibotec Pharma Enters Into Licensing Agreement With Hetero Drugs For TMC278 423
Euroscreen Enters Into Licensing Agreement With Ortho-McNeil-Janssen 424
Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharma 425
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 426
Actelion Spun Out its Drug Discovery and Early Clinical Pipeline Business 428
Alligator Bioscience Raises USD252.8 Million in IPO 429
Tesaro Raises USD50 Million in Private Placement of Shares 431
Achillion Pharma Raises USD225 Million in Private Placement of Shares 432
Minerva Neurosciences Raises USD31 Million in Private Placement of Shares 434
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 436
MacroGenics Raises USD75 Million in Private Placement of Common Stock 438
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 440
Johnson & Johnson Plans to Raise Funds through Public Offering of Notes 441
Johnson & Johnson Completes Public Offering Of Notes Due 2018 For US$600 Million 442
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$400 Million 444
Johnson & Johnson Completes Public Offering Of Notes Due 2023 For US$550 Million 446
Johnson & Johnson Completes Public Offering Of Notes Due 2033 For US$650 Million 448
Johnson & Johnson Completes Public Offering Of Notes Due 2043 For US$500 Million 450
Johnson & Johnson Completes Public Offering Of Notes Due 2016 For US$800 Million 452
Actelion Pharma Completes Private Placement Of Convertible Bonds For US$254 Million 454
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$300 Million 455
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2013 For US$500 Million 457
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$900 Million 459
Johnson & Johnson Completes Public Offering Of 0.70% Senior Unsecured Notes Due 2013 For US$500 Million 461
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 463
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$450 Million 465
Johnson & Johnson Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 467
Trimb Healthcare Acquires OTC Products from Cilag and Janssen Pharma 469
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 470
Strides Arcolab to Acquire Seven Brands from Johnson & Johnson 471
Air Liquide Acquires Healthcare Antisepsis Solutions from Ethicon 472
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 473
Vivus Acquires Topiramate Related Patents from Janssen Pharma 475
Reckitt Benckiser To Acquire K-Y Lubricants Brand From McNEIL-PPC 476
Bertin Pharma Acquires R&D Facility from Johnson & Johnson Sante Beaute France 477
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 478
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 480
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 481
Furiex Pharma Acquires Priligy From Janssen Pharmaceutica And Alza 482
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 483
Forest Labs Acquires Patents And Intellectual Property For Bystolic From Janssen Pharma For US$357 Million 484
Shire Acquires US Rights Of Resolor From Janssen Pharmaceutica 485
Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 486
Insight Pharma Acquires MONISTAT Business In North America From McNEIL-PPC 487
Ilex Consumer Products Acquires St. Joseph's Aspirin Brand From McNeil 488
Prestige Brands Completes Acquisition Of Dramamine Assets From McNeil-PPC 489
Johnson & Johnson Acquires Actelion for USD30 Billion 490
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 492
Ethicon Acquires Torax Medical 494
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 495
DePuy Orthopaedics Acquires BioMedical Enterprises 496
Johnson & Johnson Consumer to Acquire NeoStrata 497
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 498
Johnson and Johnson May Sell Noramco 499
Johnson & Johnson Acquires Novira Therapeutics 500
Biosense Webster Acquires Coherex Medical 501
Actelion Plans to Acquire ZS Pharma 502
Actelion Rejects Acquisition Offer from Shire 503
Janssen Pharma Acquires XO1 504
Valneva Acquires Crucell Sweden for USD54 Million 505
Tetraphase Pharma May Sell Itself 506
Johnson & Johnson Acquires Alios BioPharma for USD1.75 Billion 507
Cilag Acquires Covagen 509
Novartis Acquires CoStim Pharma 510
Actelion Completes Acquisition Of Ceptaris Therapeutics For US$250 Million 512
Johnson & Johnson Completes Acquisition Of Aragon Pharma For US$1 Billion 514
Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 516
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 517
Johnson & Johnson Completes Acquisition Of Shanghai Elsker For Mother & Baby 519
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 520
Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 522
Janssen-Cilag Acquires CorImmun 523
Valeant Pharma Completes Acquisition Of Ortho Dermatologics From Janssen For US$345 Million 525
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 526
SuperGen Completes Acquisition Of Astex Therapeutics 527
Johnson & Johnson Acquires Crucell 530
Johnson & Johnson, Key Competitors 532
Johnson & Johnson, Key Employees 533
Johnson & Johnson, Subsidiaries 534
List of Figures
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 22
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23
Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 24
Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 26
